Should Britain make psychedelic-assisted therapy available on the NHS?

Clinical trials at Imperial College London and other institutions have shown promising results for psilocybin and MDMA in treating severe depression and PTSD. Yet these substances remain Class A drugs, and sceptics question whether the science is mature enough to justify mainstream rollout.

Anoniem stemmen is mogelijk. Registreer voor een profiel en score.